Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0C2OR
|
|||
Former ID |
DIB011124
|
|||
Drug Name |
MIM-D3
|
|||
Synonyms |
TrkA agonist (ocular disease/Alzheimer's disease), Mimetogen
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 3 | [1] | |
Company |
Mimetogen Pharmaceuticals Inc
|
|||
Structure |
Download2D MOL |
|||
Formula |
C24H32N6O11
|
|||
Canonical SMILES |
C1COC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)NC(C(=O)NC(C(=O)NC1C(=O)NCC(=O)O)CCCCN)CCC(=O)O
|
|||
InChI |
1S/C24H32N6O11/c25-9-2-1-3-15-23(37)29-17(22(36)26-12-20(33)34)8-10-41-18-6-4-13(30(39)40)11-14(18)21(35)27-16(24(38)28-15)5-7-19(31)32/h4,6,11,15-17H,1-3,5,7-10,12,25H2,(H,26,36)(H,27,35)(H,28,38)(H,29,37)(H,31,32)(H,33,34)/t15-,16-,17-/m0/s1
|
|||
InChIKey |
DVJXNXPFYJIACK-ULQDDVLXSA-N
|
|||
CAS Number |
CAS 263251-78-1
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Tropomyosin-related kinase A (TrkA) | Target Info | Agonist | [2] |
KEGG Pathway | MAPK signaling pathway | |||
Endocytosis | ||||
Apoptosis | ||||
Neurotrophin signaling pathway | ||||
Inflammatory mediator regulation of TRP channels | ||||
Pathways in cancer | ||||
Transcriptional misregulation in cancer | ||||
Thyroid cancer | ||||
Central carbon metabolism in cancer | ||||
NetPath Pathway | IL2 Signaling Pathway | |||
Pathway Interaction Database | Neurotrophic factor-mediated Trk receptor signaling | |||
Reactome | Frs2-mediated activation | |||
ARMS-mediated activation | ||||
NGF-independant TRKA activation | ||||
PI3K/AKT activation | ||||
WikiPathways | MAPK Signaling Pathway | |||
BDNF signaling pathway | ||||
Integrated Pancreatic Cancer Pathway | ||||
NGF signalling via TRKA from the plasma membrane |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01960010) A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye. U.S. National Institutes of Health. | |||
REF 2 | Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.